Bottom line
Is HGHAX a good fund? The bottom line
HGHAX is the Class A share class of The Hartford Healthcare Fund, an actively managed health care sector mutual fund from Hartford.
Its expense ratio is 1.33% — about $133 a year on every $10,000 invested, more expensive than 75% of health care sector funds we track.
With $772 million in net assets and 80 holdings, its largest position is Eli Lilly & Co (12.0%) and the top 10 make up 47.7% of the portfolio.
This share class carries a front-end sales charge of up to 5.5%; a no-load class or ETF alternative can avoid it.
The closest lower-cost alternative we found is XLV (0.08%, 72% top-holdings overlap).
What to watch
- Expensive for its category (1.33%)
- Front-end sales load up to 5.5%
- 12b-1 marketing fee of 0.25% a year
Updated Nov 19, 2026
What HGHAX invests in
The Fund seeks long-term capital appreciation.
Under normal circumstances, the Fund invests at least 80% of its assets in the equity securities of health care-related companies worldwide as selected by the sub-adviser, Wellington Management Company LLP (Wellington Management). Wellington Managements investment process focuses on stock selection through fundamental analysis. The Fund takes a broad approach to investing in the health care sector. The Fund may invest in health-related companies, including companies in the pharmaceuticals, biotechnology, medical delivery, medical products, medical services, managed health care, health information services and emerging health-related subsectors. The Funds assets will be allocated across the major subsectors of the health care sector, with some representation typically maintained in each major subsector. The Fund will normally invest at least 25% of its total assets, in the aggregate, in…
From the fund's prospectus (filed Feb 26, 2026).
HGHAX performance
| 1 yr | 5 yr | 10 yr | |
|---|---|---|---|
| HGHAX | — | — | — |
| Health Care Sector median | +14.5% | +4.2% | +7.9% |
Source: Fund prospectus, as of
What HGHAX costs
On a $10,000 investment, HGHAX's 1.33% expense ratio costs about $133 a year. The prospectus estimates $2,063 in total costs over 10 years (assuming 5% annual returns). The median health care sector fund charges 0.96%.
HGHAX top 10 holdings
| # | Holding | % of fund |
|---|---|---|
| 1 | Eli Lilly & Co | 12.03% |
| 2 | Johnson & Johnson | 6.75% |
| 3 | Merck & Co Inc | 6.00% |
| 4 | UnitedHealth Group Inc | 4.74% |
| 5 | AbbVie Inc | 4.21% |
| 6 | Elevance Health Inc | 3.00% |
| 7 | Intuitive Surgical Inc | 2.88% |
| 8 | CVS Health Corp | 2.84% |
| 9 | Vertex Pharmaceuticals Inc | 2.64% |
| 10 | Danaher Corp | 2.57% |
Source: SEC Form N-PORT, period ended Jul 31, 2026
The top 10 make up 47.7% of the fund. See all top 25 holdings and asset mix →
Alternatives to HGHAX
| Family | Fund | Expense ratio | Overlap | |
|---|---|---|---|---|
| SPDR (State Street) | XLV State Street(R) Health Care Select… | 0.08% | 72% | Compare |
| Fidelity | FHLC Fidelity MSCI Health Care Index ETF | 0.084% | 72% | Compare |
| Vanguard | VGHCX Vanguard Health Care Fund | 0.33% | 77% | Compare |
| iShares | IYH iShares U.S. Healthcare ETF | 0.37% | 68% | Compare |
| J.P. Morgan | JDOC JPMorgan Healthcare Leaders ETF | 0.65% | 61% | Compare |
| Schwab | SWHFX Schwab Health Care Fund | 0.8% | 65% | Compare |